Our Pricing

Mysimba Reviews: What Real UK Patients and Clinical Evidence Tell Us

Published on: June 03, 2026

Reading mysimba reviews from actual patients and understanding clinical trial data helps you make an informed decision about this prescription weight loss treatment. As a UK-registered pharmacist who has supported thousands of weight management patients, I've compiled real-world feedback alongside evidence from the COR trials to give you a complete picture of what to expect from Mysimba (naltrexone/bupropion combination therapy).

What Do Mysimba Reviews from UK Patients Reveal About Effectiveness?

Mysimba reviews consistently highlight moderate but meaningful weight loss when combined with lifestyle changes. In clinical practice, patients typically report losing 5-10% of their body weight over 6-12 months, which aligns closely with the COR trial findings where 42% of participants achieved at least 5% weight loss compared to 17% on placebo[1]. Many UK patient reviews emphasise that Mysimba works best as part of a comprehensive programme including dietary modifications and increased physical activity.

Real-world mysimba reviews often mention appetite suppression and reduced food cravings as the primary mechanisms patients notice. The naltrexone component targets the brain's reward pathways whilst bupropion affects dopamine and noradrenaline signalling, creating a dual-action effect that patients describe as making it easier to stick to calorie-controlled eating plans[2]. However, individual responses vary considerably, and some patient reviews note minimal appetite changes whilst others report significant reductions in hunger and emotional eating patterns.

Common Side Effects Mentioned in Mysimba Reviews and How to Manage Them

Nausea is the most frequently cited side effect in mysimba reviews, particularly during the initial titration phase. Approximately 30-40% of patients report some degree of nausea in the first 2-4 weeks, though this typically diminishes as the body adjusts to the medication[3]. Taking Mysimba with food, staying well-hydrated, and following the gradual dose escalation schedule recommended by your prescriber can significantly reduce gastrointestinal discomfort.

Other commonly reported side effects in patient mysimba reviews include headaches (reported by around 18% of users), constipation (17%), dizziness (10%), and dry mouth[3]. Insomnia appears in some reviews, likely related to the bupropion component's stimulant properties, which is why taking the second daily tablet no later than early afternoon helps many patients. Most side effects are mild to moderate and resolve within the first month of treatment, though anyone experiencing persistent or severe symptoms should consult their prescriber immediately.

Serious Side Effects Requiring Immediate Medical Attention

Whilst rare, mysimba reviews and clinical monitoring have identified serious adverse events that require urgent medical assessment. These include signs of allergic reactions (rash, swelling, breathing difficulties), seizures (Mysimba lowers seizure threshold), severe mood changes or suicidal thoughts, visual disturbances, or symptoms of high blood pressure[4]. Any patient experiencing chest pain, irregular heartbeat, or neurological symptoms should seek immediate medical help and discontinue Mysimba pending clinical review.

Mysimba Reviews on Weight Loss Results: What Timeline to Expect

Patient mysimba reviews typically describe a gradual weight loss pattern rather than dramatic rapid results. Most users report noticing initial changes within 4-8 weeks, with more significant weight reduction becoming apparent after 12-16 weeks of consistent use[1]. The COR-I trial demonstrated that average weight loss at 56 weeks was 6.1% of baseline body weight for those completing the full treatment course, though results ranged from minimal loss to over 15% reduction depending on individual factors and lifestyle adherence.

Long-term mysimba reviews emphasise the importance of realistic expectations and sustained commitment. Weight loss plateaus are common after the initial 6 months, and maintaining results requires ongoing dietary management and physical activity. Clinical guidance suggests that if a patient hasn't achieved at least 5% weight loss after 16 weeks on the full maintenance dose, Mysimba should be discontinued as it's unlikely to provide meaningful benefit[2]. At Cured Pharmacy, we provide Mysimba at the cheapest UK price from £0.00, with all prescriptions subject to clinical assessment by our UK-registered prescribers.

How Mysimba Reviews Compare to Other Weight Loss Treatments

When comparing mysimba reviews against feedback for GLP-1 receptor agonists like semaglutide (Wegovy) or tirzepatide (Mounjaro), patients generally report that Mysimba produces more modest weight loss but with a different side effect profile. Wegovy reviews often cite greater average weight reduction (around 15% body weight) but more pronounced gastrointestinal effects, whilst Mysimba users more frequently mention central nervous system effects like headaches and insomnia[5].

Mysimba reviews also highlight the convenience of oral tablet administration compared to weekly injections required for GLP-1 medications. Some patients prefer the tablet format despite potentially lower efficacy, whilst others find the twice-daily dosing schedule less convenient than once-weekly injections. Cost considerations appear frequently in comparative reviews, with Mysimba historically positioned as a mid-range option between budget treatments like orlistat and premium GLP-1 therapies, though pricing varies significantly across UK providers.

Patient Preference Factors in Treatment Selection

Mysimba reviews reveal that treatment choice often depends on individual medical history and contraindications. Patients with uncontrolled hypertension, seizure disorders, or eating disorders cannot use Mysimba, whilst those with certain gastrointestinal conditions may struggle with GLP-1 medications[4]. Your prescriber will assess your complete medical profile to recommend the most appropriate weight loss treatment, and all options require ongoing clinical monitoring and lifestyle modification support.

Mysimba Reviews on Appetite Control and Food Cravings

One of the most consistent themes in mysimba reviews is the medication's impact on reward-driven eating behaviours. Patients frequently describe reduced cravings for high-calorie comfort foods, less emotional eating, and an increased ability to feel satisfied with smaller portions. This aligns with Mysimba's mechanism targeting the hypothalamic melanocortin system and mesolimbic reward pathways, which regulate both appetite and the pleasurable aspects of eating[2].

However, mysimba reviews also reveal considerable individual variation in appetite suppression effects. Some users report dramatic reductions in food preoccupation and snacking behaviours within the first month, whilst others notice only subtle changes or require several months to experience meaningful appetite modulation. The combination of naltrexone (an opioid antagonist) and bupropion (a dopamine/noradrenaline reuptake inhibitor) creates synergistic effects that don't manifest identically across all patients, highlighting the importance of individualised treatment approaches and realistic expectation-setting.

Expert Pharmacist Insights on Mysimba Reviews and Clinical Use

After reviewing thousands of patient experiences and clinical outcomes, the mysimba reviews that report best results consistently involve comprehensive lifestyle programmes rather than medication alone. Patients who combine Mysimba with structured dietary counselling, regular physical activity (aiming for 150+ minutes weekly), behavioural therapy, and ongoing medical monitoring achieve significantly better outcomes than those relying solely on pharmacotherapy[6]. As superintendent pharmacist Tarun Kumar (GPhC 2233073) often emphasises, weight loss medications are tools that enhance lifestyle changes rather than replacements for them.

When evaluating mysimba reviews, it's important to recognise that published testimonials may not represent typical experiences, and individual results vary based on genetics, baseline weight, metabolic health, medication adherence, and lifestyle factors. The MHRA-licensed indication for Mysimba is adjunctive treatment for weight management in adults with BMI ≥30 kg/m² (or ≥27 kg/m² with weight-related comorbidities) who haven't achieved adequate weight loss through diet and exercise alone[4]. All prescriptions require clinical assessment, and Cured Pharmacy's UK-registered clinical team provides free online consultations under 3 minutes to determine suitability before dispensing any prescription weight loss treatment.

Contraindications and Precautions Highlighted in Clinical Reviews

Professional mysimba reviews and prescribing guidance emphasise several absolute contraindications: uncontrolled hypertension, seizure disorders, current or past eating disorders (bulimia/anorexia), bipolar disorder, opioid dependence, acute alcohol or benzodiazepine withdrawal, and pregnancy or breastfeeding[4]. Patients taking MAO inhibitors or certain other medications must avoid Mysimba due to serious drug interactions. Regular blood pressure monitoring is essential during treatment, as Mysimba can elevate cardiovascular parameters in susceptible individuals. Your prescriber will conduct thorough screening to ensure Mysimba is safe and appropriate for your specific circumstances.

Scientific References

1. Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 376(9741), 595-605. [accessed 13 August 2026]
2. Apovian, C. M., Aronne, L., Rubino, D., Still, C., Wyatt, H., Burns, C., Kim, D., & Dunayevich, E. (2013). A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity, 21(5), 935-943. [accessed 13 August 2026]
3. Hollander, P., Gupta, A. K., Plodkowski, R., Greenway, F., Bays, H., Burns, C., Klassen, P., & Fujioka, K. (2013). Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care, 36(12), 4022-4029. [accessed 13 August 2026]
4. Electronic Medicines Compendium. (2023). Mysimba 8 mg/90 mg prolonged-release tablets - Summary of Product Characteristics (SmPC). Medicines and Healthcare products Regulatory Agency. [accessed 13 August 2026]
5. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 13 August 2026]
6. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE Clinical Guidelines. [accessed 13 August 2026]

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.